Blueprint medicines corporation (BPMC)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities
Net loss

-110,955

-66,331

-94,275

-99,681

-87,407

-80,322

-72,723

-27,048

-56,549

-49,027

-37,703

-33,412

-27,977

-21,263

-16,834

-18,894

-15,504

-15,575

-12,642

-12,980

-11,572

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

1,571

-2,075

2,605

3,551

1,178

1,170

1,163

1,133

780

391

396

393

398

393

407

396

386

333

204

202

209

Noncash lease expense

1,391

-

-

-

1,041

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Noncash interest expense

-

-

-

-

-

-

-

-

-

-

-

8

11

-

17

20

22

25

26

29

29

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

407

38

Stock-based compensation

16,859

15,699

14,993

13,666

10,295

8,832

8,391

7,762

5,549

3,705

3,599

2,979

2,240

1,646

1,905

1,487

1,102

1,195

971

2,174

840

Accretion of premiums and discounts on investments

-134

-583

-1,393

-1,641

-1,332

-1,447

-1,259

-983

-692

-286

-110

-10

86

97

94

75

35

-

-

-

-

Other

-

-

-

-

-

-16

2

4

4

-

-

-

-

-

-

-

-

-

-

-

-

Changes in assets and liabilities:
Accounts receivable

3,847

-1,751

1,664

363

323

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unbilled accounts receivable

-2,152

20,180

-1,946

4,144

219

-

-

-

-

-3,435

360

249

-751

-

104

-881

818

944

547

1,439

484

Inventory

382

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

1,408

-3,837

2,335

3,459

1,381

-79

-3,332

798

-3,473

6,681

-2,436

636

1,972

-597

1,233

319

-2,262

438

405

275

364

Other assets

66

-78

-121

65

114

-23

681

3,557

27

-342

804

10

-14

299

-12

28

-11

-

-

-

-

Accounts payable

3,715

2,543

-4,386

2,309

982

-689

1,029

-303

-482

1,657

-422

226

71

377

-800

-140

567

707

-97

-736

1,517

Accrued expenses

-16,576

10,572

16,414

11,202

-1,208

5,878

7,331

12,120

-525

5,521

5,123

5,505

-1,552

3,846

-275

2,523

-321

412

1,088

571

-115

Deferred revenue

-575

4,742

-3,139

-966

-731

-1,033

-1,095

8,561

-954

-1,398

-4,633

-2,815

-3,015

-4,113

-1,705

-3,715

43,127

-1,220

-957

986

14,832

Deferred rent

-

-

-

-

-

-186

-151

-163

-140

7,999

5,952

504

-135

-133

-118

-119

-118

2,456

418

37

-40

Operating lease liabilities

-1,073

61

-591

-596

-969

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-109,328

-44,895

-71,704

-81,228

-80,188

-67,582

-55,005

-2,859

-49,563

-34,750

-26,518

-27,517

-31,080

-18,797

-18,634

-17,833

30,751

-13,046

-12,465

-11,055

4,890

Purchases of property and equipment

1,525

3,891

6,182

2,170

1,770

425

2,618

3,322

6,312

10,580

4,475

247

210

18

522

552

1,262

3,754

822

288

19

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-119

-70

0

0

1,266

Purchases of investments

139,250

140,873

132,225

352,373

112,916

152,334

159,617

150,469

338,816

45,547

105,396

191,889

18,003

159,149

36,096

0

69,222

-

-

-

-

Maturities of investments

200,635

212,500

212,944

106,490

204,000

209,000

178,825

139,000

126,000

106,000

102,000

42,000

54,000

-

-

-

-

-

-

-

-

Net cash provided by investing activities

59,860

67,736

74,537

-248,053

89,314

56,241

16,590

-14,791

-219,128

49,873

-7,871

-150,136

35,787

-138,286

-15,618

5,448

-70,365

-3,684

-822

-288

-1,285

Principal payments on loan payable

-

-

-

-

-

278

417

416

417

583

583

584

833

833

833

834

833

556

417

416

417

Payment of offering costs

-

-

-

-

-

0

0

117

164

42

207

227

489

-

-

-

-

0

81

1,819

146

Proceeds from public offerings of common stock, net of commissions, underwriting discounts and offering costs

308,541

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of Series C convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

Proceeds from issuance of common stock

1,609

-

-

-

2,039

-

-

-

3,643

2,453

1,162

754

902

481

102

316

29

213

-22

49

19

Other financing activities

-

0

-44

-44

-28

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

310,150

1,834

4,495

332,298

2,011

764

113

515

3,062

327,853

372

216,143

-420

134,630

-731

-518

-804

-343

-520

154,632

-547

Net increase in cash, cash equivalents, and restricted cash

260,682

24,675

7,328

3,017

11,137

-10,577

-38,302

-17,135

-265,629

342,976

-34,017

38,490

4,287

-22,453

-34,983

-12,903

-40,418

-17,073

-13,807

143,289

3,058

Effect of exchange rate changes on cash, cash equivalents and restricted cash

50

28

-13

19

-16

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental cash flow information
Public offering costs incurred but unpaid at period end

118

-

-

-

-

-

-

-

166

217

-206

-210

516

-

-

-

-

-

-

-777

805

Property and equipment purchases unpaid at period end

465

-2,267

-103

1,850

1,478

784

-1,986

-1,012

3,126

751

1,276

1,840

80

-

-101

-128

244

-

-

-

-

Cash paid for interest

-

-

-

-

-

206

30

13

18

26

34

41

50

62

74

85

95

105

111

116

120

Cash paid for taxes, net

32

55

33

44

53

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-